ArticleBMC infectious diseases2026
Preventive effectiveness of respiratory syncytial virus vaccination in older adults: a multi-institutional cohort study.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis multi-institutional study evaluated the real-world effectiveness of respiratory syncytial virus (RSV) vaccination in preventing RSV infections among adults aged 50 and older.
methodsUsing data from the TriNetX Research Network, we included individuals aged ≥ 50 years between January 1, 2023, and May 31, 2026. Patients were categorized into vaccinated and unvaccinated groups, defined as those receiving any RSV vaccine and any non-RSV vaccine, respectively. After 1:1 propensity score matching, we estimated hazard ratios (HR) for the composite outcome of RSV infection using Cox proportional-hazards models.
resultsThe study included 179,871 patients in each group after matching. The vaccinated group had a lower risk of RSV infection compared to the unvaccinated group (incidence rate: 0.17 vs. 0.27 per 100 person-years, HR, 0.65; 95% CI, 0.58-0.73). Additionally, the vaccinated group showed lower risks of RSV-associated lower respiratory tract disease (incidence rate: 0.12 vs. 0.19 per 100 person-years, HR, 0.69; 95% CI, 0.60-0.79). Risk reductions were consistent across subgroups defined by age, sex, and comorbidity.
conclusionsThis large real-world study demonstrates the substantial effectiveness of RSV vaccination in preventing infections among older adults, a high-risk population. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.